SIU 2017: Oncologic Outcomes and Predictive Factors for Recurrence following Robot-Assisted Radical Cystectomy for Urothelial Carcinoma: Multicenter Study from Korea

Lisbon, Portugal ( In this study the authors aimed to evaluate the intermediate-term oncologic outcomes, predictive factors for recurrence, and recurrence patterns in a multicenter series of patients treated with robot-assisted radical cystectomy (RARC) for urothelial carcinoma (UC) of the bladder.

Between 2007 and 2015, a total of 346 patients underwent RARC at multiple tertiary referral centers in Korea. Median follow-up was 33 months (interquartile range [IQR]: 7—50). The number of patients with organ-confined and lymph node (LN)-positive disease were 237 (68.4%) and 68 (19.7%), respectively. LN density (1-20 versus > 20) was 13.6% and 6.1%, with a median of 17 nodes removed (IQR: 9-23). In logistic regression analysis, type of LN dissection and pathologic tumor stage were significant predictors of cancer recurrence and cancer death. Local and distant recurrence and secondary UC occurred in 7 (2.0%), 53 (15.3%), and 4 (1.2%) patients, respectively. The 5-year overall survival, cancer-specific survival, and recurrence-free survival (RFS) were 78%, 84%, and 73%, respectively. At last follow-up, RFS for extended pelvic LN dissection versus standard pelvic LN dissection was 70% and 47% (P= 0.038). 

The authors concluded that patients undergoing RARC at their centers demonstrated intermediate-term oncologic outcomes, predictive factors for recurrence, and recurrence patterns that were similar to previous studies.

Presented by: Shim Js
Affiliation: Seoul, South Korea; Kyungpook National University School of Medicine, Daegu, South Korea

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.